Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Haleon PLC - Weybridge, Surrey-based consumer healthcare firm that spun out of GSK PLC in 2022 - Agrees to acquire the remaining 12% stake in Tianjin TSKF Pharmaceutical Co Ltd, its joint venture in China, following its acquisition of a further 33% interest in December 2024. The remaining stake will be bought from partner Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd for a total of ¥1.62 billion, around $221 million. TSKF will become a wholly-owned subsidiary of Haleon.
The purchase will be funded via Haleon’s existing cash resources and new local-currency debt and is expected to close within the next three months, it said.
Current stock price: 379.40 pence, up 0.1% in London on Tuesday morning
12-month change: up 17%
Copyright 2025 Alliance News Ltd. All Rights Reserved.